| Metric | Q2 2026 | Q2 2025 |
|---|---|---|
| Net income | -57.1 | -83.1 |
| EPS (diluted, $ a share) | $-0.54 | $-0.90 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: REPL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Replimune Group, Inc.: key numbers
- Share price
- $21.41Close, Nov 16
- Market cap
- $2.03B
- Shares outstanding
- 94.8MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Replimune Group, Inc.
All →Replimune Group Insider Joseph P. Slattery Sells $113K of Stock
Joseph P. Slattery sold 5,200 shares of Replimune Group, Inc. at $21.80 a share, worth $113K in total on Nov 9, 2026. Shares held after the trade: 1,467 (-78.0%).
- Value
- $113K
- Shares
- 5,200
- Price
- $21.80
- Holding change
- -78.0%
- Trade date
- Nov 9, 2026
Replimune Group Insider Kapil Dhingra Sells $408K of Stock
Kapil Dhingra sold 21,500 shares of Replimune Group, Inc. at $19.00 a share, worth $408K in total on Nov 2, 2026. Shares held after the trade: 21,669 (-49.8%).
- Value
- $408K
- Shares
- 21,500
- Price
- $19.00
- Holding change
- -49.8%
- Trade date
- Nov 2, 2026
Replimune Group Financial Results
Replimune Group reported financial results for its fiscal second quarter 2027 and provided a commercial update on the U.S. launch of TUDRIQEV for advanced melanoma. The product became commercially available on October 6, 2026, with more than 15 institutions already prescribing the therapy and over 70% of priority accounts engaged for adoption.
- Term
- fiscal second quarter ended September 30, 2026
“TUDRIQEV is now available to patients in urgent need. The response from physicians has been enthusiastic and both oncologists and interventional radiologists are eager to bring TUDRIQEV into their practices. They value the broad label that lets them treat patients immediately after progression on a PD-1 based therapy. We are focused on reaching as many of these patients as possible.”
Sushil Patel, Ph.D., CEO of Replimune
Replimune Group Shareholder Meeting
Replimune Group held its 2026 Annual Meeting of Stockholders where shareholders approved an amendment to the Certificate of Incorporation to double the number of authorized shares of common stock from 150 million to 300 million. Stockholders also ratified the selection of PricewaterhouseCoopers LLP as the independent auditor and approved executive compensation on an advisory basis.